Different postprandial lipid metabolism and insulin resistance between non-diabetic patients with and without coronary artery disease

Journal of Cardiology

Volumn 66, Issue 5, 2015, Pages 435-444

  Nakamura, Akihiro ^a   Monma, Yuto ^a   Kajitani, Shoko ^a   Kozu, Katsuya ^a   Ikeda, Shohei ^a   Noda, Kazuki ^a   Nakajima, Sota ^a   Endo, Hideaki ^a   Takahashi, Tohru ^a   Nozaki, Eiji ^a  

^a Iwate Prefectural Central Hospital   (Japan)

Author keywords

Coronary artery disease; Hyperinsulinemia; Postprandial hyperlipidemia

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; C PEPTIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; INSULIN; LIPID; LIPOPROTEIN; REMNANT-LIKE PARTICLE CHOLESTEROL; SWEETENING AGENT;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; METABOLIC PARAMETERS; POSTPRANDIAL STATE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALYSIS; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BLOOD; COMPLICATION; FEMALE; HYPERINSULINISM; HYPERLIPIDEMIAS; MALE; METABOLISM; MIDDLE AGED; TIME FACTOR;

AGED; AREA UNDER CURVE; ATHEROSCLEROSIS; BLOOD GLUCOSE; C-PEPTIDE; CHOLESTEROL; CORONARY ARTERY DISEASE; DIET, HIGH-FAT; FEMALE; GLUCOSE; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SWEETENING AGENTS; TIME FACTORS; TRIGLYCERIDES;

EID: 84943659078     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.02.005     Document Type: Article

References (43)

1. Fuster V., Lewis A. Conner Memorial Lecture: Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994, 90:2126-2146.
2. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., Kastelein J.J., LaRosa J.C., Schachner H., Shepherd J., Waters D.D., Treating to New Targets Investigators Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006, 368:919-928.
3. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., Barnes E.H., Voysey M., Gray A., Collins R., Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
4. Iso H., Naito Y., Sato S., Kitamura A., Okamura T., Sankai T., Shimamoto T., Iida M., Komachi Y. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001, 153:490-499.
5. Fujioka Y., Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009, 16:145-154.
6. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
7. Fihn S.D., Gardin J.M., Abrams J., Berra K., Blankenship J.C., Dallas A.P., Douglas P.S., Foody J.M., Gerber T.C., Hinderliter A.L., King S.B., Kligfield P.D., Krumholz H.M., Kwong R.Y., Lim M.J., et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012, 60:e44-e164.
8. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
9. Hiramitsu S., Miyagishima K., Ishii J., Matsui S., Naruse H., Shiino K., Kitagawa F., Ozaki Y. The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012, 60:395-400.
10. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio Heart study. Diabetes Care 1997, 20:1087-1092.
11. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
12. Furugen M., Saitoh S., Ohnishi H., Akasaka H., Mitsumata K., Chiba M., Furukawa T., Miyazaki Y., Shimamoto K., Miura T. Matsuda-DeFronzo insulin sensitivity index is a better predictor than HOMA-IR of hypertension in Japanese: the Tanno-Sobetsu study. J Hum Hypertens 2012, 26:325-333.
13. Tanaka A. Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb 2004, 11:322-329.
14. Patsch J.R., Miesenbock G., Hopfewieser T., Mühlberger V., Knapp E., Dunn J.K., Gotto A.M., Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992, 12:1336-1345.
15. Kubo M., Kiyohara Y., Kato I., Tanizaki Y., Arima H., Tanaka K., Nakamura H., Okubo K., Iida M. Trend in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003, 34:2349-2354.
16. Freiberg J.J., Tybjærg-Hansen A., Jensen J.S., Nordestgaard B.G. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300:2142-2152.
17. Lemieux I., Couillard C., Pascot A., Bergeron N., Prud'homme D., Bergeron J., Tremblay A., Bouchard C., Mauriege P., Després J.P. The small dense LDL phenotype as a correlate of postprandial lipemia in men. Atherosclerosis 2000, 153:423-432.
18. Galeano N.F., Al-Haideri M., Keyserman F., Rumsey S.C., Deckelbaum R.J. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998, 39:1263-1273.
19. de Graaf J., Hak-Lemmers H.L.M., Hectors M.P.C., Demacker P.N.M., Hendriks J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991, 11:298-306.
20. Kondo A., Muranaka Y., Ohta I., Notsu K., Manabe M., Kotani K., Saito K., Maekawa M., Kanno T. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 2001, 47:893-900.
21. Wägner A.M., Jorba O., Rigla M., Alonso E., Ordóňez-Llanos J., Perez A. LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol 2002, 39:215-220.
22. Tani S., Saito Y., Anazawa T., Kawamata H., Furuya S., Takahashi H., Iida K., Matsumoto M., Washio T., Kumabe N., Nagao K., Hirayama A. Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study. Int Heart J 2011, 52:343-347.
23. Kawakami A., Yoshida M. Remnant lipoproteins and atherogenesis. J Atheroscler Thromb 2005, 12:73-76.
24. Masuda D., Sakai N., Sugimoto T., Kitazume-Taneike R., Yamashita T., Kawase R., Nakaoka H., Inagaki M., Nakatani K., Yuasa-Kawase M., Tsubakio-Yamamoto K., Ohama T., Nakagawa-Toyama Y., Nishida M., Ishigami M., et al. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb 2011, 18:1062-1070.
25. Gylling H., Miettinen T.A. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis 1996, 126:325-332.
26. Matthan N.R., Pencina M., LaRocque J.M., Jacques P.F., D'Agostino R.B., Schaefer E.J., Lichtenstein A.H. Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD. J Lipid Res 2009, 50:1927-1935.
27. Ai R., Tanaka A., Ogita K., Sekine M., Numano F., Reaven G.M. Relationship between insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J Am Coll Cardiol 2001, 38:1628-1632.
28. Roche H.M., Gibney M.J. The impact of postprandial lipemia in accelerating atherothrombosis. J Cardiovasc Risk 2000, 7:317-324.
29. Haidari M., Leung N., Mahbub F., Uffelman K.D., Kohen-Avramoglu R., Lewis G.F., Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 2002, 277:31646-31655.
30. Després J.P., Lamarche B., Mauriège P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
31. Yip J., Facchini F.S., Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998, 83:2773-2776.
32. Zavaroni I., Bonini L., Gasparini P., Barilli A.L., Zuccarelli A., DalĺAglio E., Delsignore R., Reaven G.M. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 1999, 48:989-994.
33. Kitta Y., Nakamura T., Uematsu M., Sugamata W., Deyama J., Fujioka D., Saito Y., Kawabata K., Obata J., Kugiyama K. Insulin resistance negatively affects long-term outcome in non-diabetic patients with coronary artery disease after therapies to reduce atherosclerotic risk factors. J Cardiol 2013, 62:348-353.
34. Rajpathak S.N., Kumbhani D.J., Crandall J., Barzilai N., Alderman M., Ridker P.M. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
35. Allison B.G. Statins: is it really time to reassess benefits and risk?. N Engl J Med 2012, 366:1752-1755.
36. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
37. Stone N.J., Robinson J.G., Lichtenstein A.H., Merz N.B., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D.G., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., et al. 2013 ACC/AHA guideline on treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline. J Am Coll Cardiol 2014, 63:2889-2934.
38. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
39. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefèbvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
40. Sawada T., Shiotani H., Terashita D., Nagasawa Y., Kim S.S., Koide M., Yokoyama M. Comparison of effects of α-glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetes patients with coronary artery disease. Circ J 2014, 78:248-255.
41. Miettinen T.A., Gylling H., Lindbohm N., Miettinen T.E., Rajaratnam R.A., Relas H., Finnish Treat-to-Target Study Investigators Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141:131-137.
42. Borggreve S.E., Hillege H.L., Wolffenbuttel B.H., de Jong P.E., Bakker S.J., van der Steege G., van Tol A., Dullaart R.P., PREVEND Study Group. The effect of cholesteryl ester transfer protein -629C>A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab 2005, 90:4198-4204.
43. Targher G., Alberiche M., Zenere M.B., Bonadonna R.C., Muggeo M., Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:3619-3624.